No Data
Due to restricted share units received, Genor Biopharma-B (06998) issued 0.125 million shares.
Jahwa Biological-B (06998) announced that on October 28, 2024, the company selected participants for...
Jiawei Bio - B [06998] is now trading at HKD 2.02, with a rise of 10.99%.
As of 13:47, KaHe Bio-B [06998] reported a price of 2.02 Hong Kong dollars, up 0.2 Hong Kong dollars or 10.99% from the closing price of 1.82 Hong Kong dollars yesterday. The turnover was 0.7659 million Hong Kong dollars. The highest price today is 2.02 Hong Kong dollars, and the lowest price is 1.8 Hong Kong dollars. Based on the closing price yesterday, the 10-day average price is 1.81 Hong Kong dollars, and the 50-day average price is 1.47 Hong Kong dollars. The current P/E ratio is -1.24 times, and the 14-day relative strength index is 60.00.
Yiteng Jia and "Transformation", the first shot of "value leap" was fired in the cold winter of biomedical capital.
With this integration, the new company's dual advantages in R&D and commercialization will make it more in line with the current market valuation trend for Biopharma companies, thereby possessing the potential for value reconstruction.
Jiahe Biotech-B (06998) has reached a major acquisition agreement with Yiteng Medicine, boosting the development of domestic innovative drugs.
On October 7th, Jiahao Biology-B (06998) announced a heavy acquisition with Yiteng Medicine, expecting to bring complementary and synergistic effects to both parties, and lay a good foundation for the sustainable development of the enlarged group after the merger is completed.
Hong Kong stock market anomaly | Jiahe Life Sciences-B (06998) resumed trading with a nearly 88% high opening, planning to acquire Yiteng Pharmaceuticals Group through consolidation. The company will be renamed as 'Yiteng Jiahe'.
Jiahe Biology-B (06998) resumed trading today, opening nearly 88% higher in the morning. As of the time of writing, it has risen by 87.88%, trading at 3.1 Hong Kong dollars, with a turnover of 1.1811 million Hong Kong dollars.
Express News | Genor Biopharma - Consideration of Proposed Merger Is to Be Wholly Settled by Way of Issuing Consideration Shares
No Data
No Data
